Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07357441 · ClinicalTrials.gov registry record
A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 355
- Enrollment target
NCT07357441 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 355 participants.
The verdict
NCT07357441 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 355 participants
- Enrollment target
Study Summary
This was a non-interventional retrospective study. Data from patients who were diagnosed with myelofibrosis (MF) (primary MF, post-polycythemia vera MF \& post-essential thrombocythemia MF) and treated with ruxolitinib for at least 3 months collectively were collected. The baseline visit was the visit that the patient started ruxolitinib treatment. Data was collected between January 01, 2015 and December 31, 2022. The main baseline clinical and laboratory data of the cohort with at least 3 months of ruxolitinib treatment was documented in order to identify real life patient data in Turkey. All the data was transferred to a clinical report form (CRF), then to the Statistical Package for the Social Sciences (SPSS) software in an anonymous fashion. The source documents were secured for quality control of the data. The quality control of the data was controlled by an unbiased data entry coordinator.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2022-04-07 |
| Est. Completion | 2023-06-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07357441
The ClinicalTrials.gov registry entry for NCT07357441 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07357441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07357441 about?
NCT07357441 is a clinical study titled "A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey". This was a non-interventional retrospective study. Data from patients who were diagnosed with myelofibrosis (MF) (primary MF, post-polycythemia vera MF \& post-essential thrombocythemia MF) and treated with ruxolitinib for at least 3 months collectively were collected. The baseline visit was the vis...
What is the current status of trial NCT07357441?
This trial is currently completed. The enrollment target is 355 participants. The study started on 2022-04-07. Estimated completion is 2023-06-28.
Who is sponsoring clinical trial NCT07357441?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.